G.N.Airloop signed a loan agreement for fund-raising on June 26, 2026, with financial covenants set to maintain capital and achieve profitability from the fiscal year ending December 2026 onward. The funds raised amount to 20,000 million yen, with collateral provided in the form of subsidiary shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"G.N.Airloop","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/2160-20260626-01.pdf","jir_short_summary":"G.N.Airloop signed a loan agreement for fund-raising on June 26, 2026, with financial covenants set to maintain capital and achieve profitability from the fiscal year ending December 2026 onward. The funds raised amount to 20,000 million yen, with collateral provided in the form of subsidiary shares.","jir_summary":"### Fundraising and Contract Details\nG.N.Airloop entered into a loan agreement for 20,000 million yen on June 26, 2026, scheduled to be executed on July 1, 2026. The lenders are Mizuho Bank and SBI Shinsei Bank, with collateral provided in the form of ordinary shares of its subsidiary Gyre Therapeutics, Inc. The agreement includes financial covenants requiring the company to maintain total capital of at least 75% from the fiscal year ending December 2026 onward and to ensure that consolidated operating profit or net income does not turn negative. The funds are intended for expenses related to acquiring shares of Aum Pharmaceutical Holdings. The impact on future performance is under review.\n\n### Outlook and Impact\nThe funds raised are intended to finance the acquisition of shares of Aum Pharmaceutical Holdings, with financial covenants requiring the company to maintain financial soundness and profitability. Completion of the fundraising and adherence to contract conditions are expected to significantly influence future business operations and financial stability. G.N.Airloop will continue to focus on capital policy and financial management to ensure stable performance and growth.","jir_financial_highlights":"Loan amount: 20,000 million yen (Unknown)\nCollateral details: Ordinary shares of Gyre Therapeutics, Inc. (Unknown)\nLoan execution date: 2026-07-01 (Unknown)","jir_category":"","jir_hashtags":"#G.N.Airloop, #FinancialResults, #JapanStocks","jir_key_figures":"Loan amount: 20,000 million yen\nCollateral details: Ordinary shares of Gyre Therapeutics, Inc.\nLoan execution date: 2026-07-01","jir_meta_title":"\u3010G.N.Airloop\u3011Details of Fundraising and Financial Covenants | June 2026","jir_meta_description":"G.N.Airloop signed a loan agreement for 20,000 million yen in June 2026, setting financial covenants to maintain capital and achieve profitability. Impact on future performance.","jir_og_title":"\u3010G.N.Airloop\u3011Details of Fundraising and Financial Covenants | June 2026","jir_og_description":"G.N.Airloop entered into a loan agreement for 20,000 million yen in June 2026. It set financial covenants to maintain capital and achieve profitability, with attention on future performance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-71922","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n